Abstract
Prostate cancer (PCa) continues to trend among top 3 cancers that kill men over 20 years in the United Kingdom and worldwide despite extensive research and resources directed towards its treatment and prevention. In the application of a hallmark of survival mechanisms by the cancer, our study used mRNA seq data to identify genes that are increasingly mutated with progressing PCa from a cohort of 491 PCa patients. We found that ENOX1, CCDC122 and LACC1 deep deletion was positively associated with increasing age of diagnosis. Pathway analysis of enriched genes, following their deep deletion identified estrogen biosynthesis, KSRP signalling, omega 3 and 6 fatty acid biosynthesis and, Rap1 signalling as the top 5 enriched pathways. Previous individual and combined role of these genes in PCa progression was not fully established but thanks to this study, these pathways could be druggable targets in PCa patients with these gene deep deletions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.cbioportal.org/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
https://www.cbioportal.org/study/summary?id=prad_tcga
